Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The prophylactic and therapeutic efficacy of the broadly active antiviral ribonucleoside N4-Hydroxycytidine (EIDD-1931) in a mouse model of lethal Ebola virus infection.
Bluemling GR, Mao S, Natchus MG, Painter W, Mulangu S, Lockwood M, De La Rosa A, Brasel T, Comer JE, Freiberg AN, Kolykhalov AA, Painter GR. Bluemling GR, et al. Among authors: painter w. Antiviral Res. 2023 Jan;209:105453. doi: 10.1016/j.antiviral.2022.105453. Epub 2022 Nov 13. Antiviral Res. 2023. PMID: 36379378 Free article.
Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients.
Florescu DF, Pergam SA, Neely MN, Qiu F, Johnston C, Way S, Sande J, Lewinsohn DA, Guzman-Cottrill JA, Graham ML, Papanicolaou G, Kurtzberg J, Rigdon J, Painter W, Mommeja-Marin H, Lanier R, Anderson M, van der Horst C. Florescu DF, et al. Among authors: painter w. Biol Blood Marrow Transplant. 2012 May;18(5):731-8. doi: 10.1016/j.bbmt.2011.09.007. Epub 2011 Sep 29. Biol Blood Marrow Transplant. 2012. PMID: 21963623 Free PMC article.
Development of CMX001 for the Treatment of Poxvirus Infections.
Lanier R, Trost L, Tippin T, Lampert B, Robertson A, Foster S, Rose M, Painter W, O'Mahony R, Almond M, Painter G. Lanier R, et al. Among authors: painter w, painter g. Viruses. 2010 Dec;2(12):2740-2762. doi: 10.3390/v2122740. Viruses. 2010. PMID: 21499452 Free PMC article.
First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses.
Painter W, Robertson A, Trost LC, Godkin S, Lampert B, Painter G. Painter W, et al. Among authors: painter g. Antimicrob Agents Chemother. 2012 May;56(5):2726-34. doi: 10.1128/AAC.05983-11. Epub 2012 Mar 5. Antimicrob Agents Chemother. 2012. PMID: 22391537 Free PMC article. Clinical Trial.
Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2.
Painter WP, Holman W, Bush JA, Almazedi F, Malik H, Eraut NCJE, Morin MJ, Szewczyk LJ, Painter GR. Painter WP, et al. Among authors: painter gr. Antimicrob Agents Chemother. 2021 May 1;65(5):e02428-20. doi: 10.1128/AAC.02428-20. Epub 2021 Mar 1. Antimicrob Agents Chemother. 2021. PMID: 33649113 Free PMC article.
Population pharmacokinetics of molnupiravir in adults with COVID-19: Lack of clinically important exposure variation across individuals.
Bihorel S, Cao Y, Chawla A, Birger R, Maas BM, Gao W, Roepcke S, Sardella S, Humphrey R, Kondragunta S, Jayaraman B, Martinho M, Painter W, Painter G, Holman W, De Anda C, Brown ML, Johnson MG, Paschke A, Rizk ML, Stone JA. Bihorel S, et al. Among authors: painter w. CPT Pharmacometrics Syst Pharmacol. 2023 Dec;12(12):1859-1871. doi: 10.1002/psp4.13031. Epub 2023 Oct 5. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37798914 Free PMC article. Clinical Trial.
Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
FitzGerald R, Dickinson L, Else L, Fletcher T, Hale C, Amara A, Walker L, Penchala SD, Lyon R, Shaw V, Greenhalf W, Bullock K, Lavelle-Langham L, Reynolds H, Painter W, Holman W, Ewings S, Griffiths G, Khoo S. FitzGerald R, et al. Among authors: painter w. Clin Infect Dis. 2022 Aug 24;75(1):e525-e528. doi: 10.1093/cid/ciac199. Clin Infect Dis. 2022. PMID: 35271729 Free PMC article. Clinical Trial.
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.
Fischer WA 2nd, Eron JJ Jr, Holman W, Cohen MS, Fang L, Szewczyk LJ, Sheahan TP, Baric R, Mollan KR, Wolfe CR, Duke ER, Azizad MM, Borroto-Esoda K, Wohl DA, Coombs RW, James Loftis A, Alabanza P, Lipansky F, Painter WP. Fischer WA 2nd, et al. Among authors: painter wp. Sci Transl Med. 2022 Jan 19;14(628):eabl7430. doi: 10.1126/scitranslmed.abl7430. Epub 2022 Jan 19. Sci Transl Med. 2022. PMID: 34941423 Free PMC article. Clinical Trial.
31 results